Virginia A. Schad, PharmD, RPh

How does ongoing, long-term depression affect lung function decline and respiratory disease mortality in middle-aged and older adults?

What is the real-world effectiveness of reslizumab in preventing eosinophilic asthma exacerbations, both in those switching biologic therapies and in biologic-naïve patients?

In children and adolescents with asthma, how does medical follow-up within 14 days of an asthma-related ED visit affect the rate of subsequent ED revisits?

Is there an association between COPD and functional gastrointestinal disorders, including GERD, irritable bowel syndrome, and functional dyspepsia?

In patients with idiopathic pulmonary fibrosis, can supplementation with vitamins C, D, and E affect respiration, inflammation, and oxidative stress?

Is the presence of asthma in adults who have experienced maltreatment as children mediated by lifetime depressive and/or anxiety disorders?

Does omalizumab therapy for patients with moderate to severe allergic asthma affect these patients’ use of antitussives?

What is the difference in efficacy between mepolizumab and benralizumab, 2 biologics approved for the treatment of severe eosinophilic asthma?

Researchers examined BLOCK COPD trial data to explore whether COPD exacerbation risk was associated with baseline bronchodilator response or early reduction in FEV1/FVC.

A meta-analysis evaluated the safety and effectiveness of methylprednisolone in treatment of COVID-19 patients.

Can long-COVID lung diseases be better understood and classified via analysis of abnormalities seen on transbronchial lung cryobiopsies?

Does alternating NIV with high flow nasal oxygen reduce mortality or intubation rates in immunocompromised patients with acute respiratory failure?

How do substance abuse and depression affect the risk for premature mortality in patients with common chronic respiratory and other conditions?

How have social distancing and other interventions to prevent the spread of COVID-19 affected pediatric asthma exacerbations?

How effective is home-based pulmonary rehabilitation in addressing dyspnea-related anxiety and distress in patients with COPD?

Does pulmonary inflammation resulting from airborne toxicants trigger immune system activation in individuals with asthma and COPD?

Researchers in South Korea found poverty and pre-existing respiratory conditions were among the diverse risk factors for hospital-acquired pneumonia.

A study of infant bronchiolitis identified metatranscriptome profiles and their relationship with host transcriptome and future asthma development.

A Scottish study examined the need for psychosocial support post ICU discharge among patients who have recovered from severe COVID-19.

In patients with COVID-19, visual assessment of computed tomography images may be useful in predicting the severity of illness.

The MANDALA phase 3 trial assesses the efficacy and safety of an inhaler combining albuterol with budesonide for reducing asthma exacerbations.

RECOVERY, a large, randomized clinical trial, assessed the efficacy of colchicine, a proposed treatment for inflammation associated with COVID-19.

A meta-trial of 6 clinical trials evaluated the efficacy of awake prone positioning in preventing intubation and death in patients with severe COVID-19.

A recent Chinese study sought to identify clinical predictors of pulmonary hypertension combined with obstructive sleep apnea.

Does use of CPAP or high-flow nasal oxygen by inpatients with COVID-19 expose nearby healthcare workers to a greater risk of viral contamination?

A better understanding of the physiologic pathways affected by COPD may lead to new biomarkers for predicting exacerbations and new therapeutic targets.

For children with asthma, does visiting an asthma specialist significantly improve asthma control?

The STAR clinical trial explored the safety and efficacy of once-daily aspirin for improving surrogate outcomes of acute respiratory distress syndrome.

A phase 2a trial assessed the efficacy and safety of the monoclonal antibody risankizumab, which targets subunit p19 of IL-23, in adults with severe asthma.

An Egyptian study of patients with asthma assessed the prevalence of selective IgA deficiency and its correlation to recurrent infections in these patients.